Hutchison China MediTech Limited

HUTCHMED (China) Limited discovers develops and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib an inhibitor for non-small cell lung cancer (NSCLC) papillary and renal cell carcinoma colorectal cancer (CRC) and gastric cancer (GC); and Fruquintinib an inhibitor for CRC breast cancer GC endometrial cancer (EMC) NSCLC hepatocellular carcinoma and gastrointestinal and solid tumors. It also develops Surufatinib an inhibitor for neuroendocrine tumors (NET) pancreatic NET non-pancreatic NET biliary tract cancer sarcoma neuroendocrine neoplasm esophageal cancer small cell lung cancer GC thyroid cancer EMC NSCLC and solid tumors; HMPL-523 a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition it develops Tazemetostat an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306 an inhibitor for hematological malignancies gliomas and solid tumors; HMPL-760 an Bruton's tyrosine kinase inhibitor; HMPL-453 an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83 an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ) Lilly (Shanghai) Management Company Limited BeiGene Inmagene Biopharmaceuticals Co. Ltd. Innovent Biologics Co. Inc. Genor Biopharma Co. Ltd. Shanghai Junshi Biosciences Co. Ltd. and Epizyme Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central Hong Kong.